Ani Pharmaceuticals
(NASDAQ) ANIP
Ani Pharmaceuticals Financials at a Glance
Market Cap
$1.86B
Revenue (TTM)
$923.71M
Net Income (TTM)
$89.67M
EPS (TTM)
$3.94
P/E Ratio
20.72
Dividend
$0.00
Beta (Volatility)
0.76 (Low)
Dividend
$0.00
Beta (Volatility)
0.76 (Low)
Price
$81.55
Volume
179,751
Open
$82.10
Price
$81.55
Volume
179,751
Open
$82.10
Previous Close
$81.68
Daily Range
$80.75 - $83.66
52-Week Range
$62.14 - $99.50
Estimated Earnings Date
Aug 7, 2026
Dividend
$0.00
Beta (Volatility)
0.76 (Low)
Price
$81.55
Volume
179,751
Open
$82.10
Previous Close
$81.68
Daily Range
$80.75 - $83.66
52-Week Range
$62.14 - $99.50
Estimated Earnings Date
Aug 7, 2026
ANIP News
ANIP: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Ani Pharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareEmployees
970
CEO
Nikhil Lalwani, MBA
Website
www.anipharmaceuticals.comHeadquarters
Baudette, MN 56623, US
ANIP Financials
Key Financial Metrics (TTM)
Gross Margin
66%
Operating Margin
13%
Net Income Margin
10%
Return on Equity
17%
Return on Capital
10%
Return on Assets
6%
Earnings Yield
4.83%
Dividend Yield
0.00%
Payout Ratio
0.84%
Stock Overview
Market Cap
$1.86B
Shares Outstanding
22.75M
Volume
179.75K
Avg. Volume
350.57K
Financials (TTM)
Gross Profit
$450.64M
Operating Income
$81.23M
EBITDA
$207.27M
Operating Cash Flow
$185.23M
Capital Expenditure
-$34.32M
Free Cash Flow
$150.90M
Cash & ST Invst.
$285.59M
Total Debt
$325.20M
Ani Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$237.46M
+20.5%
Gross Profit
$122.96M
-0.9%
Gross Margin
51.78%
N/A
Market Cap
$1.86B
N/A
Market Cap/Employee
$2.07M
N/A
Employees
897
N/A
Net Income
$29.49M
+88.1%
EBITDA
$57.37M
+18.6%
Quarterly Fundamentals
Total Cash
$311.18M
+100.5%
Total Debt
$327.76M
-47.4%
Accounts Receivable
$255.43M
+15.9%
Inventory
$143.47M
+4.4%
Long Term Debt
$308.47M
-49.6%
Short Term Debt
$19.30M
+72.4%
Return on Assets
6.31%
N/A
Return on Invested Capital
10.45%
N/A
Free Cash Flow
$47.05M
+210.7%
Operating Cash Flow
$58.38M
+66.8%